{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:05:47Z","timestamp":1788879947678,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]},{"name":"Key Research and Development Project of Zhejiang Province","award":["No. 2023C03046."],"award-info":[{"award-number":["No. 2023C03046."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11473-6","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:22:35Z","timestamp":1755613355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Qin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"11473_CR1","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"M-F Yuen","year":"2018","unstructured":"Yuen M-F, et al. Hepatitis B virus infection. Nat Rev Dis Primer. 2018;4:18035.","journal-title":"Nat Rev Dis Primer"},{"issue":"Suppl 1","key":"11473_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/liv.14359","volume":"40","author":"ML Shiffman","year":"2020","unstructured":"Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int. 2020;40(Suppl 1):22\u20136.","journal-title":"Liver Int"},{"key":"11473_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-2003-37591","volume":"23","author":"RJ Fontana","year":"2003","unstructured":"Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis. 2003;23:89\u2013100.","journal-title":"Semin Liver Dis"},{"key":"11473_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","volume":"14","author":"R-N Chien","year":"2022","unstructured":"Chien R-N, Liaw Y-F. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14:434.","journal-title":"Viruses"},{"issue":"Suppl 2","key":"11473_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jvh.14032","volume":"31","author":"GL-H Wong","year":"2024","unstructured":"Wong GL-H. Updated guidelines for the prevention and management of chronic hepatitis B-World Health Organization 2024 compared with China 2022 HBV guidelines. J Viral Hepat. 2024;31(Suppl 2):13\u201322.","journal-title":"J Viral Hepat"},{"key":"11473_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving Entecavir treatment. Hepatology. 2017;66:335\u201343.","journal-title":"Hepatology"},{"key":"11473_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.14309\/ajg.0000000000002181","volume":"118","author":"J Yang","year":"2023","unstructured":"Yang J, et al. Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis. Am J Gastroenterol. 2023;118:1010\u20138.","journal-title":"Am J Gastroenterol"},{"key":"11473_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, et al. Tenofovir alafenamide versus Tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11473_CR9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","volume":"42","author":"J Lim","year":"2022","unstructured":"Lim J, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B. Liver Int. 2022;42:1517\u201327.","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"11473_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/liv.14848","volume":"41","author":"M Buti","year":"2021","unstructured":"Buti M, Marcos-Fosch C, Esteban R. Nucleos(t)ide analogue therapy: the role of tenofovir alafenamide. Liver Int. 2021;41(Suppl 1):9\u201314.","journal-title":"Liver Int"},{"key":"11473_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update. J Hepatol. 2021;75:659\u201389.","journal-title":"J Hepatol"},{"key":"11473_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.14218\/JCTH.2022.00098","volume":"10","author":"N-L Kang","year":"2022","unstructured":"Kang N-L, et al. Advantages of a novel model for predicting hepatic fibrosis in chronic hepatitis B virus carriers compared with APRI and FIB-4 scores. J Clin Transl Hepatol. 2022;10:412\u20139.","journal-title":"J Clin Transl Hepatol"},{"key":"11473_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.14218\/JCTH.2023.00272","volume":"11","author":"J Zhou","year":"2023","unstructured":"Zhou J, et al. Antiviral therapy favors a lower risk of liver cirrhosis in HBeAg-negative chronic hepatitis B with normal alanine transaminase and HBV DNA positivity. J Clin Transl Hepatol. 2023;11:1465\u201375.","journal-title":"J Clin Transl Hepatol"},{"key":"11473_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10238-019-00560-z","volume":"19","author":"R Liu","year":"2019","unstructured":"Liu R, et al. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year Entecavir therapy. Clin Exp Med. 2019;19:309\u201320.","journal-title":"Clin Exp Med"},{"key":"11473_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119:486\u201396.","journal-title":"Am J Gastroenterol"},{"key":"11473_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u201381.","journal-title":"J Hepatol"},{"key":"11473_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2024.03.006","volume":"81","author":"AT Ma","year":"2024","unstructured":"Ma AT, et al. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis. J Hepatol. 2024;81:441\u201350.","journal-title":"J Hepatol"},{"key":"11473_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jvh.13500","volume":"28","author":"MS Farag","year":"2021","unstructured":"Farag MS, et al. Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: real-world study. J Viral Hepat. 2021;28:942\u201350.","journal-title":"J Viral Hepat"},{"key":"11473_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/14787210.2018.1428561","volume":"16","author":"M Vigan\u00f2","year":"2018","unstructured":"Vigan\u00f2 M, Loglio A, Grossi G, Lampertico P. Tenofovir Alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Rev Anti Infect Ther. 2018;16:153\u201361.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"11473_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, Tenofovir disoproxil fumarate, and Tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23:384.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11473-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:06:57Z","timestamp":1757477217000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11473-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11473"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11473-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the guidelines of the institutional ethics committee and adhered to the tenets of the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, China, with a waiver of informed consent granted(approval number: KY2024-101). The registration date is April 24, 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1039"}}